Skip to content
Aortic stenosis
Wara Samar

5th February 2025

Abbott Launches Navitor Vision in India: Advancing Treatment for Aortic Stenosis

Abbott has introduced the Navitor Vision in India, a next-generation transcatheter aortic valve designed for patients with symptomatic severe aortic stenosis who face high or extreme surgical risks. This latest advancement in Abbott’s Navitor transcatheter aortic valve implantation (TAVI) system enhances visibility and precision during procedures, reinforcing the company’s commitment to innovative cardiovascular solutions. 

Aortic stenosis, one of the most prevalent and life-threatening heart valve diseases, limits blood flow from the heart to the rest of the body. Left untreated, it can lead to heart failure and reduced life expectancy. In India, one in 40 people aged 75 and older experience this condition, making effective treatment options crucial. Historically, surgical aortic valve replacement was the standard approach, but not all patients could withstand open-heart surgery due to age, frailty, or other underlying health conditions. 

The Benefits of TAVI and Navitor Vision 

TAVI has emerged as a transformative, minimally invasive alternative, enabling valve replacement without the need for open-heart surgery. Unlike traditional procedures, TAVI is performed through small incisions, often in the groin, allowing for quicker recovery times, reduced hospital stays, and improved overall patient outcomes. With the introduction of Navitor Vision, Abbott is further advancing this technology by integrating three large Vision markers that enhance valve visibility and aid precise deployment during implantation. This ensures greater accuracy for interventionists, ultimately leading to safer and more effective procedures. 

The Navitor Vision valve is designed to accommodate a broad range of patient needs, with sizes that fit heart openings (annulus) from 19 mm to 27 mm. It features a dynamic sealing cuff that minimizes blood leakage back into the heart, a key factor in optimizing long-term valve performance. Additionally, Abbott’s FlexNav™ delivery system, known for its slim design, allows treatment of patients with vessels as small as 5.0 mm, making the procedure accessible to a wider patient population. 

Long-Term Benefits and Future Readiness 

A 30-day outcome study has demonstrated the effectiveness of the Navitor valve, highlighting its excellent hemodynamics, meaning it facilitates efficient blood flow with minimal resistance. Its design includes large frame cells that enable easy access to coronary arteries, ensuring the potential for future coronary interventions when needed. These attributes position Navitor as a long-term solution for patients requiring heart valve replacement. 

Abbott’s ongoing innovation in structural heart treatments continues to expand options for patients with heart valve disease, providing less invasive alternatives that improve quality of life. With Navitor Vision now available in India, more patients can benefit from this cutting-edge technology, reinforcing Abbott’s leadership in cardiovascular care and its mission to enhance patient outcomes through advanced medical solutions. 

MedTech World is in Dubai this February!  

On February 23-24, MedTech World will host 300+ C-level executives, 100+ investors, 70+ speakers, and 50+ startup founders in Dubai for discussions and networking. Spaces are limited. Reserve your spot before registration closes.

MedTech Dubai 2025